We randomized 60 patients with methicillin-resistant Staphylococcus aureus bacteremia to treatment with vancomycin or vancomycin and flucloxacillin. The mean bacteremia duration was 3.0 and 1.9 days in the standard and combination therapy groups respectively (P=0.06). Further trials are warranted. 
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BACKGROUND
Invasive methicillin-resistant Staphylococcus aureus (MRSA) infection imposes a substantial burden on healthcare systems throughout the world [1] . A recent national Australian study conducted over one year found that 450 of 1,994 episodes (24%) of S. aureus bacteremia were caused by MRSA [2] .
More importantly, this study found that the all-cause 30-day mortality was 30% for MRSA compared with 17.7% for methicillin-susceptible S. aureus (MSSA; p<0.001). Studies from elsewhere have also reported infection with MRSA to have a higher mortality than MSSA [3] . The reasons for this difference in outcome are unclear, but may relate to differences in host factors [4] or to the limitations of vancomycin, the most commonly used antibiotic for invasive MRSA infections [5] .
Compared with the anti-staphylococcal β-lactam oxacillin and its derivatives for treatment of MSSA infections, vancomycin demonstrates slower bacterial killing [6] , poorer tissue penetration [7] , slower clearance of bacteremia [8] , and is associated with higher mortality [9] . In recent years, several alternative agents to vancomycin have become available for the treatment of MRSA bacteremia, including linezolid, daptomycin, and ceftaroline. Each of these has been found to be non-inferior to vancomycin for selected MRSA infections, but none have been shown to be superior for MRSA bacteremia [10] and are all associated with a high cost and/or a substantial risk of adverse effects.
An alternative strategy to improve outcomes from MRSA bacteremia is to combine vancomycin with a second agent, aiming for synergistic bacterial killing. Unfortunately, neither daptomycin nor Thus there is considerable in vitro and limited animal model evidence to suggest that the combination of vancomycin and an anti-staphylococcal β-lactam may be more effective than vancomycin alone for MRSA bacteremia. In a retrospective analysis, Dilworth et al. described a higher rate of clearance of MRSA bacteremia in patients receiving empiric vancomycin plus a β-lactam compared to patients receiving vancomycin alone [14] . However, no prospective human clinical studies addressing this question have been performed. We therefore conducted a pilot randomized controlled trial (RCT), to assess feasibility, proof of concept and safety of this strategy.
Objectives
We hypothesized that the anti-staphylococcal β-lactam flucloxacillin combined with vancomycin would have a greater clinical efficacy compared to vancomycin alone in patients with MRSA bacteremia. The primary objective of this study was to determine and compare the average duration in days of MRSA bacteremia by allocated treatment.
METHODS

Study design and setting
We performed a pilot, multicenter, open-label, parallel group RCT at seven Australian hospitals (see acknowledgements section for details). Participants were recruited between January 2011 and May 2014. Institutional ethics approval was obtained at each site, and written informed consent was obtained from the participant or a surrogate decision maker prior to enrolment in the study. The 
Randomization and masking
Randomization was stratified by site, with a 1:1 treatment allocation using permuted blocks of variable size. Randomization codes were computer generated by the trial statistician who had no involvement in the day to day running of the trial. Allocation concealment was achieved using sequentially numbered opaque sealed double envelopes. guidelines [16] . The total duration of vancomycin was clinician-determined.
Procedures
Outcomes and measurements
The primary endpoint was the duration of MRSA bacteremia in days. Secondary endpoints were: (1) Combined safety endpoint of nephrotoxicity (a rise in serum creatinine of >50% from baseline) or hepatotoxicity (plasma alanine transaminase or gamma-glutaryl transferase >2.5x the upper limit of A c c e p t e d M a n u s c r i p t 7 normal) within the first 10 days post randomization; (2) All cause 28-day and 90-day mortality; (3) Relapsed bacteremia during the index hospital admission (defined as a positive blood culture for MRSA ≥48 hours after a preceding negative blood culture); (4) Metastatic complications during the first 10 days; and (5) Requirement for ICU admission OR development of septic shock after randomization. Post-hoc secondary endpoints were duration of bacteremia >3 days and >7 days.
Blood cultures were collected daily for the first seven days of the study in all patients. Those with a positive blood culture on study day seven had ongoing blood cultures collected every 48 h until they became negative. Blood was also collected for routine analyses and vancomycin levels on days 1-7 inclusive and on day 10.
Laboratory methods
Oxacillin and vancomycin Etest® (bioMérieux, Marcy l'Etoile, France) minimum inhibitory concentrations (MICs) for each bacterial isolate were determined according to manufacturer's instructions. We genotyped the isolates by a coagulase gene PCR-Restriction Fragment Length Polymorphisms assay, contour clamped Homogenous Electric Field Electrophoresis [17] , binary typing [18] , and spa sequence typing on selected isolates. These typing results were used to assign a predicted multi-locus sequence type (ST). The binary typing method was also used to determine the presence of the gene encoding Panton-Valentine leucocidin [18] .
Sample size
A sample size of 60 was calculated to determine the duration of bacteremia in each group with a 95% confidence interval of +/-2 days, assuming that the duration of bacteremia has a normal distribution with a standard deviation of 5.1 days (derived from Fowler at al. [19] ) and a 10% correction factor for drop-out.
Statistical Methods
The primary efficacy analysis compared the duration of bacteremia from randomization by treatment group. We defined the duration of bacteremia as the time in days from randomization until one day following the last positive BC. For example, if the last positive BC was on the third day at Charles Darwin University on October 7, 2015 http://cid.oxfordjournals.org/ Downloaded from A c c e p t e d M a n u s c r i p t 8 following randomization, the duration of bacteremia was four days. If the BC obtained on the day of randomization was negative for bacterial growth, the duration of bacteremia was considered to be one day. As the duration of bacteremia was not normally distributed, but rather had a negative binomial distribution, we analysed these data using a generalized linear model with a negative binomial link. A negative binomial distribution can be thought of as the number of failures until the r th success. In our case it is the number of days of bacteremia before the first (r=1) day of persistently negative blood cultures [20] . The estimate of the effect of the combination therapy is the ratio of the mean duration in the two interventions. The duration of bacteremia was also assessed with a time to event analysis, including a Kaplan-Meier plot and a Cox model in which deaths, prior to the resolution of bacteremia, were treated as censored observations. A sensitivity analysis where the deaths were treated as a competing risk was also performed. Binary secondary outcomes were analysed using a chi-square test and the result presented as a relative risk. 
Role of the funding source
The funders of the study had no role in study design, data collection, data analysis, data interpretation, or writing of the report. JSD and SYCT had full access to all the data in the study and had final responsibility for the decision to submit for publication. In the intention to treat (ITT) population, the mean duration of bacteremia was 3.00 (sd 3.35) days in the standard therapy group and 1.94 (sd 1.79) days in the combination group (Table 3 ). The distribution of duration of bacteremia in both groups followed a negative binomial distribution (Figure 1b ) (logrank test, P=0.14). When the 3 deaths prior to clearance of bacteremia were treated as a competing risk, the hazard ratio was 0.75 (95% CI 0.50, 1.13).
RESULTS
Between
Analysis by pre-specified subgroups did not reveal any statistically significant differences, but suggested a greater benefit in the subgroup infected with S. aureus with vancomycin MIC ≥1.5µg/mL than in those with vancomycin MIC <1.5µg/mL; and also in those with HCA-MRSA genotypes compared to those with CA-MRSA genotypes (Supplementary Table 1 ).
There was no significant difference between groups in hospital, 28 or 90 day mortality, relapsed bacteremia, the incidence of nephrotoxicity or hepatotoxicity, development of septic shock or need for ICU, or metastatic complications (Table 4) .
CONCLUSIONS
Our findings support the continued investigation of combining an anti-staphylococcal β-lactam with vancomycin for MRSA bacteremia. We found a non-statistically significant reduction of one day in the duration of bacteremia in the combination therapy group, and that fewer patients had persistent bacteremia at days 3 and 7 following randomization. Although the study was not powered to A c c e p t e d M a n u s c r i p t 11 determine if these differences were statistically significant, the differences warrant further investigation in larger numbers of patients.
Notably, participants in the two allocated treatment groups were well matched with regards to baseline demographics, comorbidities and clinical syndromes. There were more patients with linerelated and native osteoarticular infections in the combination therapy group, and all three pleuropulmonary infections were in the standard therapy group. However, illness severity was similar in both groups. The groups were also balanced in terms of mean serum vancomycin levels, MRSA isolate MICs to vancomycin and oxacillin, and S. aureus genotypes.
The trend to reduction in duration of bacteremia with combination therapy was consistent in both the ITT and per-protocol groups. For the pre-specified subgroups, the direction of effect was also towards a shorter duration of bacteremia with combination therapy in all subgroups. For the subgroup where infection was due to MRSA with vancomycin MIC ≥1.5µg/mL, the duration of bacteremia for the four patients receiving standard therapy was 1, 2, 4, and 9 days and for the two patients receiving combination therapy was 1 and 2 days. If there is indeed a greater benefit for combination therapy in the group with vancomycin MIC≥1.5 µg/mL, this would be consistent with in vitro studies where synergy is more consistently seen for isolates with higher vancomycin MICs [11].
Prior to this trial, there have been retrospective reports suggesting that the addition of β-lactams for MRSA bacteremia may be beneficial. Patients with persistent MRSA bacteremia during treatment with daptomycin, appear to quickly clear their bacteremia with the addition of nafcillin or oxacillin [22] or ceftaroline [23] . In a single-center retrospective cohort, Dilworth et al. compared 50 patients with MRSA bacteremia who received combination therapy with vancomycin and at least 24 h of β-lactam, and 30 patients who received vancomycin alone. They found a higher rate of microbiological eradication in the combination therapy group (96 vs. 80%, P=0.02) [14] . Thus the results of our trial extend the existing clinical experience in combining β-lactams with standard therapy of either vancomycin or daptomycin for MRSA bacteremia.
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An additional therapeutic agent may increase the risk for adverse effects. Acute interstitial nephritis is a known, albeit uncommon, adverse effect of anti-staphylococcal β-lactams [24] . In the setting of peri-operative prophylaxis, Challagundla et al. found that high-dose compared to low-dose flucloxacillin (both with gentamicin) was associated with renal impairment [25] . Although we found no statistically significant increase in renal impairment in the combination therapy group, there were 8 (28%) cases of a rise in serum creatinine of >50% over baseline with combination therapy compared to 3 (11%) cases in the standard therapy group. Close monitoring of renal impairment will be essential for future studies of combination therapy.
Strengths of this study include the randomized, multi-center design, well-matched groups, and inclusion of detailed bacterial genotypic and MIC investigations. As this was designed as a pilot proof of feasibility study, the sample size is too small to make clinical recommendations. Even if we had found a statistically significant reduction in the duration of bacteremia with combination therapy, without clinically relevant endpoints there would be no cause to change practice. The experience with gentamicin is salutary. A trial demonstrating that adding gentamicin to standard therapy reduced the duration of bacteremia by one day but did not affect mortality [26] , still led to a widespread practice to use gentamicin in this setting [27] . More recent data has confirmed a lack of mortality benefit [28] and indeed increased nephrotoxicity with the addition of gentamicin [29] .
Hence we feel it is important that β-lactam based combination therapy is not adopted as standard clinical practice for MRSA bacteremia until and unless stronger evidence of safety and efficacy emerges from subsequent RCTs.
In conclusion, our study provides an encouraging signal that the combination of vancomycin with an A c c e p t e d M a n u s c r i p t b. These are considered healthcare-associated MRSA genotypes.
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TABLES
c. These are considered community-associated MRSA genotypes. 
Note:
Duration of bacteremia in days follows a negative binomial distribution.
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